Cell Therapy News

Nina Bhardwaj, MD, PhD, received the Lifetime Achievement in Cancer Research award from American Association of Indian Scientists in Cancer Research.

The FDA approved lisocabtagene maraleucel for treatment of adults with relapsed or refractory large B-cell lymphoma after one prior therapy.

CHICAGO — Second-line therapy with lisocabtagene maraleucel induced initial complete remission among more than half of patients with relapsed or refractory transplant-ineligible large B-cell lymphoma, results from a phase 2 trial showed.

CHICAGO — A single dose of an investigational chimeric antigen receptor T-cell therapy induced an objective response in nearly 90% of patients with relapsed or refractory multiple myeloma, phase 1 study results showed.

An investigational CRISPR/Cas9 gene-edited cell therapy demonstrated significant, durable efficacy among patients with transfusion-dependent beta-thalassemia and sickle cell disease, according to study results.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

CHICAGO – Healio gathered the best, brightest and boldest group of oncologists during the ASCO Annual Meeting in Chicago to celebrate our inaugural Healio Disruptive Innovators.

The FDA granted regenerative medicine advanced therapy designation to ALLO-501, a chimeric antigen receptor T-cell therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma.

CHICAGO — A novel chimeric antigen receptor T-cell therapy has elicited objective responses among the first 10 patients who received the treatment, according to results from the phase 1 POLARIS trial presented at ASCO Annual Meeting.

CHICAGO — A single dose of a novel chimeric antigen receptor T-cell therapy induced objective response among all treated patients with relapsed or refractory multiple myeloma, according to study results presented at ASCO Annual Meeting.